Streetbeat News

Products Services

ALGS

Aligos Therapeutics presented clinical and nonclinical data at the AASLD Liver Meeting 2023, showing that its drug ALG-055009 has a favorable risk-benefit profile. This could potentially impact the company's stock as investors react to the positive news regarding the drug's development.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:05 pm

DXR

Daxor Corporation has announced the presentation of data from a Phase I NIH-sponsored trial at the American Heart Association Annual Meeting. The data is likely to be significant for the company's profile in the medical community and could influence investor perception.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:03 pm

IPA

ImmunoPrecise's subsidiary BioStrand has published a preprint of its white paper on Biorxiv.org, titled 'New Paradigm For Biological Sequence Retrieval Inspired By Natural Language Processing And Database Research'.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:01 pm

MDGS

Medigus' subsidiary, Metagramm, is set to develop Bubbl, an AI-powered writing and grammar tool. This move signals Medigus' entry into the AI-driven content creation market, potentially expanding its product offerings and market reach.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:56 pm

COST

LQR House has partnered with Cabal Tequila for a marketing and awareness campaign, which could lead to COSTCO shelf placement in California through their partnership with Alpha Distro.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:38 pm

ALZN

Alzamend Neuro has indicated to Benzinga that the safety aspects of its AL001 development could be eligible for a 505(b)(2) New Drug Application (NDA) pathway with the FDA, which may streamline the approval process.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:31 pm

ALZN

Alzamend Neuro has submitted an IND application for a Phase IIA clinical trial for its drug candidate AL001, aimed at treating Post-Traumatic Stress Disorder (PTSD). This submission marks a significant step for the company in the development of next-generation lithium therapeutics.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:30 pm

ROIV

Roivant Sciences plans to announce further clinical results for its two drugs, 1402 and brepocitinib, in the last quarter of the year.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:12 pm

BA

Royal Jordanian has placed an order for four Boeing 787-9 Dreamliner jets and reconfirmed a previous order for two more, totaling six 787-9s on backlog. The financial terms of the deal were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:58 am

WBX

Wallbox (WBX) has expanded its partnership with Sonepar to advance the energy transition, providing installers with access to advanced, user-friendly, and efficient charging solutions.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 11:54 am